Shenzhen Kaifa Technology
920029
Shanghai Yongli Belting
300230
Guomai Culture & Media
301052
4
WuHan Hvsen Biotechnology
300871
5
CHANGFU CO.,LTD
871396
US Stock MarketDetailed Quotes
ACRS Aclaris Therapeutics
- 1.590
- -0.030-1.85%
Close Mar 28 16:00 ET
- 1.590
- 0.0000.00%
Post 16:05 ET
171.96MMarket Cap-0.93P/E (TTM)
1.665High1.580Low541.51KVolume1.630Open1.620Pre Close877.82KTurnover0.82%Turnover RatioLossP/E (Static)108.15MShares5.17052wk High1.11P/B105.42MFloat Cap0.95252wk Low--Dividend TTM66.30MShs Float33.880Historical High--Div YieldTTM5.25%Amplitude0.590Historical Low1.621Avg Price1Lot Size
Aclaris Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Current assets | ||||||||||
| Cash, cash equivalents and short term investments | -4.63%113.59M | -4.63%113.59M | 23.94%127.72M | -7.25%111.09M | -24.96%128.17M | -45.26%119.11M | -45.26%119.11M | -58.46%103.05M | -51.82%119.78M | -4.91%170.8M |
| -Cash and cash equivalents | -38.39%24.57M | -38.39%24.57M | 22.06%47.65M | -26.70%22.83M | -19.86%35.84M | -11.92%39.88M | -11.92%39.88M | -36.68%39.04M | -54.37%31.15M | 23.06%44.72M |
| -Short-term investments | 12.36%89.02M | 12.36%89.02M | 25.09%80.07M | -0.41%88.26M | -26.77%92.33M | -54.02%79.23M | -54.02%79.23M | -65.66%64.01M | -50.86%88.63M | -12.00%126.08M |
| Receivables | 6.71%318K | 6.71%318K | -0.87%343K | -24.59%325K | -45.63%373K | -38.43%298K | -38.43%298K | -42.04%346K | -32.34%431K | 8.37%686K |
| -Accounts receivable | 6.71%318K | 6.71%318K | -0.87%343K | -24.59%325K | -45.63%373K | -38.43%298K | -38.43%298K | -42.04%346K | -32.34%431K | 8.37%686K |
| Other current assets | 27.37%12.04M | 27.37%12.04M | -78.32%4.27M | -51.16%6.22M | -47.18%6.8M | -29.96%9.45M | -29.96%9.45M | 148.55%19.67M | 25.86%12.73M | 21.14%12.87M |
| Total current assets | -2.25%125.95M | -2.25%125.95M | 7.53%132.33M | -11.51%117.64M | -26.59%135.34M | -44.35%128.86M | -44.35%128.86M | -52.03%123.07M | -48.74%132.94M | -3.42%184.36M |
| Non current assets | ||||||||||
| Net PPE | -37.78%1.01M | -37.78%1.01M | -35.77%1.13M | -31.91%1.29M | 1.19%1.53M | 47.41%1.62M | 47.41%1.62M | 54.06%1.76M | 48.82%1.9M | 18.48%1.51M |
| -Gross PPE | 0.54%5.81M | 0.54%5.81M | -8.72%5.81M | -7.85%5.81M | 2.55%5.87M | 12.62%5.78M | 12.62%5.78M | 27.11%6.37M | 26.74%6.31M | 18.85%5.72M |
| -Accumulated depreciation | -15.45%-4.81M | -15.45%-4.81M | -1.65%-4.68M | -2.52%-4.52M | -3.04%-4.34M | -3.15%-4.16M | -3.15%-4.16M | -19.12%-4.6M | -19.13%-4.41M | -18.99%-4.21M |
| Goodwill and other intangible assets | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -1.07%6.92M | -1.08%6.94M | -1.08%6.95M |
| -Other intangible assets | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -1.07%6.92M | -1.08%6.94M | -1.08%6.95M |
| Investments and advances | 43.86%90.3M | 43.86%90.3M | -45.54%45.71M | -57.38%38.78M | -1.20%33.2M | 412.75%62.77M | 412.75%62.77M | --83.94M | 1,160.10%90.99M | 40.27%33.6M |
| Other non current assets | -26.26%3.07M | -26.26%3.07M | 20.89%3.22M | 16.52%3.37M | 22.05%4M | 52.20%4.16M | 52.20%4.16M | -8.93%2.66M | -7.26%2.89M | -3.22%3.28M |
| Total non current assets | 37.68%94.38M | 37.68%94.38M | -47.46%50.06M | -57.71%43.44M | -14.59%38.73M | 197.44%68.55M | 197.44%68.55M | 761.61%95.29M | 451.57%102.71M | 27.21%45.34M |
| Total assets | 11.61%220.33M | 11.61%220.33M | -16.47%182.39M | -31.65%161.07M | -24.22%174.07M | -22.46%197.41M | -22.46%197.41M | -18.41%218.35M | -15.23%235.65M | 1.40%229.71M |
| Liabilities | ||||||||||
| Current liabilities | ||||||||||
| Payables | -47.17%4.69M | -47.17%4.69M | -20.58%7.66M | -36.38%7.27M | 31.99%10.81M | -14.23%8.88M | -14.23%8.88M | 25.84%9.65M | 100.33%11.43M | 0.85%8.19M |
| -accounts payable | -47.17%4.69M | -47.17%4.69M | -20.58%7.66M | -36.38%7.27M | 31.99%10.81M | -14.23%8.88M | -14.23%8.88M | 25.84%9.65M | 100.33%11.43M | 0.85%8.19M |
| Current accrued expenses | -26.45%11.43M | -26.45%11.43M | -79.21%2.12M | -25.11%3.62M | 5.23%4.87M | 356.14%15.54M | 356.14%15.54M | 91.44%10.19M | 3.27%4.84M | 32.14%4.63M |
| Current debt and capital lease obligation | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -59.53%310K | -38.19%458K | -15.78%603K |
| -Current capital lease obligation | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -59.53%310K | -38.19%458K | -15.78%603K |
| Current deferred liabilities | --7.82M | --7.82M | --3.77M | ---- | ---- | --0 | --0 | ---- | ---- | ---- |
| Other current liabilities | 2.09%2.68M | 2.09%2.68M | 21.12%2.67M | 20.39%2.65M | 22.84%2.71M | 19.35%2.63M | 19.35%2.63M | 0.00%2.2M | 0.00%2.2M | 0.00%2.2M |
| Current liabilities | 2.08%31.6M | 2.08%31.6M | -31.13%18.82M | -31.31%15.68M | 9.98%20.08M | 41.09%30.95M | 41.09%30.95M | 38.06%27.32M | 40.77%22.83M | 9.16%18.26M |
| Non current liabilities | ||||||||||
| Non current deferred liabilities | --20.04M | --20.04M | 5,671.66%21.18M | ---- | ---- | --0 | --0 | 0.00%367K | 0.00%367K | 0.00%367K |
| Other non current liabilities | 41.68%13.14M | 41.68%13.14M | -64.34%12.25M | -64.63%11.57M | -65.07%11.97M | -73.25%9.27M | -73.25%9.27M | 24.23%34.33M | 27.55%32.7M | 17.22%34.27M |
| Total non current liabilities | 257.74%33.18M | 257.74%33.18M | -3.67%33.43M | -65.02%11.57M | -65.44%11.97M | -73.53%9.27M | -73.53%9.27M | 23.91%34.7M | 27.16%33.07M | 17.01%34.64M |
| Total liabilities | 61.02%64.77M | 61.02%64.77M | -15.77%52.24M | -51.25%27.25M | -39.41%32.05M | -29.40%40.23M | -29.40%40.23M | 29.77%62.02M | 32.39%55.9M | 14.18%52.9M |
| Shareholders'equity | ||||||||||
| Share capital | 0.00%1K | 0.00%1K | 0.00%1K | 0.00%1K | 0.00%1K | 0.00%1K | 0.00%1K | 0.00%1K | 0.00%1K | 0.00%1K |
| -common stock | 0.00%1K | 0.00%1K | 0.00%1K | 0.00%1K | 0.00%1K | 0.00%1K | 0.00%1K | 0.00%1K | 0.00%1K | 0.00%1K |
| -Preferred stock | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Retained earnings | -17.13%-902.86M | -17.13%-902.86M | -4.81%-806.31M | -7.93%-798.72M | -10.87%-787.74M | -12.97%-770.8M | -12.97%-770.8M | -17.51%-769.31M | -16.59%-740.04M | -15.68%-710.48M |
| Paid-in capital | 14.03%1.06B | 14.03%1.06B | 1.00%936.03M | 1.31%933.01M | 4.79%930.11M | 5.36%928.08M | 5.36%928.08M | 5.80%926.77M | 5.63%920.9M | 11.60%887.64M |
| Gains losses not affecting retained earnings | 191.51%97K | 191.51%97K | 137.82%427K | 58.33%-463K | -2.82%-364K | 88.18%-106K | 88.18%-106K | 22.94%-1.13M | 16.21%-1.11M | 63.58%-354K |
| Total stockholders'equity | -1.03%155.55M | -1.03%155.55M | -16.75%130.15M | -25.55%133.82M | -19.68%142.01M | -20.46%157.18M | -20.46%157.18M | -28.89%156.33M | -23.75%179.75M | -1.88%176.81M |
| Total equity | -1.03%155.55M | -1.03%155.55M | -16.75%130.15M | -25.55%133.82M | -19.68%142.01M | -20.46%157.18M | -20.46%157.18M | -28.89%156.33M | -23.75%179.75M | -1.88%176.81M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Market Insights
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025